Lajos Pusztai, MD, PhD, Yale Cancer Center, discusses DNA abnormalities in breast cancer.
Pusztai says there are only three types of abnormalities that oncologists can pick up. The best examples of FDA-approved drugs for breast cancer are HER2-amplification and HER2-targeted therapies, such as trastuzumab.
Some abnormalities have also been successfully targeted in other diseases, such as EGFR mutations, which can be targeted with gefitinib in lung cancer.
A common and important question is whether or not the abnormalities in breast cancer confer the same degree of sensitivity to a targeted drug, as they do in other disease types, says Pusztai.
Lajos Pusztai, MD, PhD, professor of medicine (medical oncology), chief of Breast Medical Oncology, co-director, Cancer Genetics Research Program, Yale Cancer Center, discusses DNA abnormalities in breast cancer.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer
April 20th 2024During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.
Read More